Summary of results, mean ± SD
Enhancing Areas | Perilesional Hyperintensity | NAWM | Pa | Pb | 95% CI | |
---|---|---|---|---|---|---|
ADCc | ||||||
TDLs | 0.83 ± 0.15 | 1.56 ± 0.11 | 0.76 ± 0.06 | .02d | .81 | 0.74–0.92 |
High-grade gliomas | 1.01 ± 0.25 | 1.54 ± 0.2 | 0.79 ± 0.06 | 0.90–1.13 | ||
pc | ||||||
TDLs | 1.44 ± 0.26 | 2.7 ± 0.19 | 1.31 ± 0.10 | .02d | .81 | 1.29–1.59 |
High-grade gliomas | 1.76 ± 0.44 | 2.67 ± 0.34 | 1.37 ± 0.11 | 1.56–1.96 | ||
qc | ||||||
TDLs | 0.25 ± 0.07 | 0.36 ± 0.05 | 0.55 ± 0.06 | .004d | .55 | 0.21–0.30 |
High-grade gliomas | 0.33 ± 0.07 | 0.38 ± 0.07 | 0.54 ± 0.07 | 0.30–0.37 | ||
Lc | ||||||
TDLs | 1.46 ± 0.26 | 2.7 ± 0.18 | 1.43 ± 0.11 | .016d | .83 | 1.31–1.62 |
High-grade gliomas | 1.79 ± 0.43 | 2.7 ± 0.34 | 1.46 ± 0.09 | 1.60–1.99 | ||
FA | ||||||
TDLs | 0.21 ± 0.06 | 0.44 ± 0.33 | 0.47 ± 0.07 | .341 | .052 | 0.17–0.25 |
High-grade gliomas | 0.23 ± 0.06 | 0.51 ± 0.09 | 0.45 ± 0.06 | 0.20–0.27 | ||
rCBV | ||||||
TDLs | 2.11 ± 1.12 | – | .003d | 1.47–2.76 | ||
High-grade gliomas | 3.77 ± 1.65 | – | 3.02–4.52 |